Ann: Quarterly Activity Report and Appendix 4C, page-3

Highlights
• CT:VQ™, the world’s first and only non-contrast, CT-based ventilation-perfusion imaging technology,
cleared by the U.S. Food and Drug Administration (FDA) for clinical use in the United States
• Centers for Medicare & Medicaid Services (CMS) confirms reimbursement for CT:VQ™ at US$650.50 per
scan, effective immediately, accelerating path to broad market adoption
• Less than two months after FDA clearance, Stanford University becomes the first U.S. Academic
Medical Centre (AMC) to adopt CT:VQ™ for clinical use under a commercial contract
• AstraZeneca partnership expands to six hospitals covering 48,000 CT scans annually for lung health
screening program in Brazil
• Key Australian contracts secured including Spectrum Medical Imaging extending multi-year agreement
to support the National Lung Cancer Screening Program
• Major publication in American Journal of Respiratory and Critical Care Medicine demonstrates XV LVAS®
accurately predicts pneumothorax risk in COPD patients undergoing bronchoscopic lung volume
reduction
• 4DMedical currently delivering SaaS products at 409 sites globally, up 50.9% year-on-year (YoY),
producing over 74,345 scans in Q1 FY26, up 105.6% YoY
• Operating revenue for Q1 FY26 of $1.4 million, with gross margins over 90%
• Continued cost reduction, with net operating cash outflows for Q1 FY26 $0.5 million favourable
quarter-on-quarter (QoQ)
• Strong cash balance of $33.5 million at 30 September 2025, with further opportunity for $30.2m of
additional capital inflows on the exercise of outstanding ASX-listed options (ASX:4DXO) with expiry date
of 31 December 2025